Alternatives to Dental Opioid Prescribing After Tooth Extraction
Launched by DOUGLAS OYLER · Feb 16, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Although use of nonsteroidal antiinflammatory drugs and acetaminophen is recommended first-line by the American Dental Association and American Association of Oral and Maxillofacial Surgeons, dentists and oral surgeons are leading prescribers of opioids to adolescents and young adults (AYA), who are at high risk for developing problematic opioid use after an initial exposure. This multi-site, stepped wedge cluster-randomized trial will assess whether a multicomponent behavioral intervention can influence opioid prescribing behavior among dentists and oral surgeons compared to usual practice...
Gender
ALL
Eligibility criteria
- Inclusion Criteria (Provider):
- • Actively U.S. licensed dentist or oral surgeon practicing at a participating cluster. Participating clinics were finalized prior to the beginning of the study based on the following criteria: (1) perform tooth extractions on at least 70 AYA patients during a 5-month screening period from July 1, 2022 through November 30, 2022 and (2) electronically prescribe opioids to at least 30% of AYA patients who underwent extraction during the screening period. Additionally, each participating cluster signed a data use agreement (DUA) for sharing electronic health record data, can provide the necessary electronic health record data, and agreed to comply with study procedures and be available for the duration of the study.
- • Provide a signed and dated informed consent form.
- • Willing to comply with all study procedures and be available for the duration of the study.
- Inclusion Criteria (Patient):
- • Undergoes any tooth extraction at a participating cluster during the study (intervention condition, transition period, or control condition) between 6-10 days earlier.
- • Age 12-25 at the time of tooth extraction.
- • Reads and acknowledges survey cover letter in lieu of a full consent/assent process.
- • Can access the electronic survey using an internet-capable device.
- Exclusion Criteria:
- • There are no other exclusion criteria for clusters or provider/patient participants that meet all inclusion criteria.
About Douglas Oyler
Douglas Oyler is a dedicated clinical trial sponsor with a commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapies and treatments, the organization collaborates with leading research institutions and healthcare professionals to conduct rigorous clinical trials across various therapeutic areas. Douglas Oyler emphasizes ethical practices, patient safety, and scientific integrity, ensuring that every study is designed to generate meaningful data that contributes to the development of effective healthcare solutions. Through its strategic partnerships and expert team, Douglas Oyler aims to drive breakthroughs that enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lexington, Kentucky, United States
Patients applied
Trial Officials
Douglas R Oyler, PharmD
Principal Investigator
University of Kentucky
Marcia V Rojas Ramirez, DDS
Principal Investigator
University of Kentucky
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported